Can Epclusa (sofosbuvir/velpatasvir) be used in people with cirrhosis?
Epclusa can be used in patients with cirrhosis. The prescribing information includes use across compensated and decompensated liver disease, including people with cirrhosis in real-world HCV treatment settings.
What if the cirrhosis is decompensated?
For decompensated cirrhosis, treatment decisions depend on whether the patient is given Epclusa with ribavirin. In practice, clinicians select a regimen based on the degree of liver failure and prior treatment history, and they monitor closely for safety and liver-related complications.
What liver function level matters (compensated vs decompensated)?
Cirrhosis status is central because decompensated disease raises the risk of worsening liver function during treatment. Epclusa’s labeling and guidance differentiate regimens by cirrhosis severity, which is why the same product can be used in cirrhosis but with different partner drugs or monitoring intensity.
Are there safety monitoring concerns in cirrhosis patients?
Yes. People with cirrhosis are monitored for:
- Liver-related changes during treatment
- Anemia and related complications when ribavirin is part of the regimen (in decompensated cases)
- Signs of hepatic decompensation or other serious adverse events
What else must be checked before prescribing Epclusa in cirrhosis?
Clinicians also check:
- Baseline hepatitis C genotype (when relevant to the regimen)
- Prior HCV treatment history
- Kidney function (because it affects whether certain components are appropriate)
- Drug-drug interactions (Epclusa can interact with some medicines used for other conditions)
Source context (patent/drug reference)
DrugPatentWatch.com tracks manufacturer and product information for hepatitis C therapies, including Epclusa. You can use it as an additional reference point for product/market context. [1]
Sources
- DrugPatentWatch.com – Epclusa (sofosbuvir/velpatasvir)